MX2022010193A - Moleculas dirigidas a proteina ras. - Google Patents

Moleculas dirigidas a proteina ras.

Info

Publication number
MX2022010193A
MX2022010193A MX2022010193A MX2022010193A MX2022010193A MX 2022010193 A MX2022010193 A MX 2022010193A MX 2022010193 A MX2022010193 A MX 2022010193A MX 2022010193 A MX2022010193 A MX 2022010193A MX 2022010193 A MX2022010193 A MX 2022010193A
Authority
MX
Mexico
Prior art keywords
ras protein
molecules targeting
targeting ras
aspects
sheet
Prior art date
Application number
MX2022010193A
Other languages
English (en)
Inventor
Filip Maria Hendrik Claes
Joost Schymkowitz
Frederic Rousseau
Original Assignee
Aelin Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aelin Therapeutics filed Critical Aelin Therapeutics
Publication of MX2022010193A publication Critical patent/MX2022010193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

Aspectos de la invención se refieren a moléculas que aparecen de manera no natural configuradas para formar una lámina-beta intermolecular con una proteína RAS humana, así como aplicaciones terapéuticas de las mismas.
MX2022010193A 2020-02-19 2021-02-19 Moleculas dirigidas a proteina ras. MX2022010193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20158306 2020-02-19
PCT/EP2021/054125 WO2021165456A1 (en) 2020-02-19 2021-02-19 Molecules targeting ras protein

Publications (1)

Publication Number Publication Date
MX2022010193A true MX2022010193A (es) 2022-11-14

Family

ID=69726430

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022010193A MX2022010193A (es) 2020-02-19 2021-02-19 Moleculas dirigidas a proteina ras.
MX2022010191A MX2022010191A (es) 2020-02-19 2021-02-19 Moleculas dirigidas a proteina ras mutante.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010191A MX2022010191A (es) 2020-02-19 2021-02-19 Moleculas dirigidas a proteina ras mutante.

Country Status (12)

Country Link
US (2) US20230100941A1 (es)
EP (2) EP4106785A1 (es)
JP (2) JP2023514420A (es)
KR (2) KR20220143702A (es)
CN (2) CN115427057A (es)
AU (2) AU2021223702A1 (es)
BR (2) BR112022016517A2 (es)
CA (2) CA3170658A1 (es)
IL (2) IL295623A (es)
MX (2) MX2022010193A (es)
WO (2) WO2021165452A1 (es)
ZA (1) ZA202209632B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
WO2007071789A1 (en) 2005-12-22 2007-06-28 Vib Vzw Means and methods for mediating protein interference
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
LT2683419T (lt) 2011-03-11 2018-07-25 Vib Vzw Molekulės ir būdai baltymo slopinimui ir aptikimui
WO2016154047A2 (en) * 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
US20180282397A1 (en) * 2016-12-15 2018-10-04 University Of Southern California Polypeptides that bind activated ras proteins
US11771749B2 (en) * 2017-02-03 2023-10-03 The Medical College Of Wisconsin, Inc. KRAS peptide vaccine compositions and method of use
EP3684799A1 (en) * 2017-09-20 2020-07-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hla class ii restricted t cell receptors against mutated ras

Also Published As

Publication number Publication date
EP4106785A1 (en) 2022-12-28
IL295623A (en) 2022-10-01
JP2023514420A (ja) 2023-04-05
EP4106787A1 (en) 2022-12-28
CA3170658A1 (en) 2021-08-26
CA3171925A1 (en) 2021-08-26
KR20220143701A (ko) 2022-10-25
WO2021165456A1 (en) 2021-08-26
BR112022016517A2 (pt) 2022-10-11
MX2022010191A (es) 2022-11-14
KR20220143702A (ko) 2022-10-25
CN115916234A (zh) 2023-04-04
US20230090247A1 (en) 2023-03-23
ZA202209632B (en) 2024-01-31
US20230100941A1 (en) 2023-03-30
WO2021165452A1 (en) 2021-08-26
CN115427057A (zh) 2022-12-02
IL295634A (en) 2022-10-01
JP2023516137A (ja) 2023-04-18
AU2021222972A1 (en) 2022-08-25
BR112022016513A2 (pt) 2022-10-11
AU2021223702A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
PH12019502870A1 (en) Small molecule modulators of human sting
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PH12018502429A1 (en) Antibody molecules for cancer treatment
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
EA201990598A1 (ru) Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201991997A1 (ru) Комбинированная терапия
EA202191280A1 (ru) Конструкции для доставки для трансцитоза и связанные способы
EA201891573A1 (ru) Конъюгат терапевтических ферментов
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
EA201992516A1 (ru) Способ получения бифункциональных белков и их производных
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2022010193A (es) Moleculas dirigidas a proteina ras.
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
EA202192488A1 (ru) Антитела против tsg-6 и их применения
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.
ATE536368T1 (de) Konjugate von zytotoxischen verbindungen mit peptiden
WO2020139788A3 (en) Targeted delivery of therapeutic molecules